DemoFictional company and invented evidence, run through the real methodology.
Quillon Therapeutics: all evidence
Claims are grouped by state, most important first. Each table lists every source checked for the claim, how it reads against what Quillon Therapeutics states, and the decision the methodology reached.
Potential gap · 1
Sources represent the claim differently from the company, with enough evidence to say so.
-
Found for its own name
Search: “Quillon Therapeutics”: quillon.example is the first result
Inspect evidenceHide evidenceClaim:
Search: “Quillon Therapeutics” → findable_for → quillon.example is the first resultNot yet confirmed by the companyFound for its own name · Quillon Therapeutics states: “quillon.example is the first result” Source Representation Assessment Exposure Captured Search resultsPerceived quillon.example is the first result Aligned High 2 Sept 2026 AI answer · assistant BPerceived Not stated Not found High 31 Aug 2026 Decision: Potential gap · Missing · 0 independent supporting origins
Unresolved · 4
Not enough independent evidence to decide. Unknown is not treated as wrong.
-
Lead programme stage
QL-101: QL-101 in Phase 1
Inspect evidenceHide evidenceClaim:
QL-101 → pipeline_stage → QL-101 in Phase 1Not yet confirmed by the companyLead programme stage · Quillon Therapeutics states: “QL-101 in Phase 1” Source Representation Assessment Exposure Captured Company websiteObserved QL-101 in Phase 1 Current High 4 Sept 2026 AI answer · assistant APerceived Preclinical Conflict High 2 Sept 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 45% · 0 independent supporting origins · flagged for human review
-
Latest funding
Series A, €32m (2026)
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → funding → Series A, €32m (2026)Not yet confirmed by the companyLatest funding · Quillon Therapeutics states: “Series A, €32m (2026)” Source Representation Assessment Exposure Captured Company newsroomObserved Series A, €32m (2026) Current Low 26 Aug 2026 AI answer · assistant BPerceived Not stated Not found High 24 Aug 2026 AI answer · assistant CPerceived Not stated Not found Medium 22 Aug 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 60% · 0 independent supporting origins
-
Research partnership
Research collaboration with Aldermoor University Hospital
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → partnership → Research collaboration with Aldermoor University HospitalNot yet confirmed by the companyResearch partnership · Quillon Therapeutics states: “Research collaboration with Aldermoor University Hospital” Source Representation Assessment Exposure Captured Company websiteObserved Research collaboration with Aldermoor University Hospital Current High 23 Aug 2026 Industry publicationEvidenced Not stated Not found Medium 21 Aug 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 60% · 0 independent supporting origins
-
Company size
11–50 employees
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → employee_range → 11–50 employeesNot yet confirmed by the companyCompany size · Quillon Therapeutics states: “11–50 employees” Source Representation Assessment Exposure Captured LinkedIn company pageObserved 11–50 employees Current Medium 5 Sept 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 60% · 0 independent supporting origins
Aligned · 6
Important sources represent the claim as the company states it.
-
Primary category
Clinical-stage biotechnology company
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → primary_category → Clinical-stage biotechnology companyNot yet confirmed by the companyPrimary category · Quillon Therapeutics states: “Clinical-stage biotechnology company” Source Representation Assessment Exposure Captured Company websiteObserved Clinical-stage biotechnology company Current High 7 Sept 2026 Industry publicationEvidenced Clinical-stage biotech developing RNA therapies Aligned Medium 3 Sept 2026 CrunchbaseEvidenced Biotechnology company Aligned Medium 5 Sept 2026 AI answer · assistant APerceived Biotechnology company developing RNA therapies Aligned High 1 Sept 2026 AI answer · assistant BPerceived Rare-disease drug developer Partial High 30 Aug 2026 Decision: Aligned · P(stated value is true) 98% · representations accurate 88% · 2 independent supporting origins
-
Founding team
Dr. Elena Varga, Dr. Samir Haddad
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → founded_by → Dr. Elena Varga, Dr. Samir HaddadNot yet confirmed by the companyFounding team · Quillon Therapeutics states: “Dr. Elena Varga, Dr. Samir Haddad” Source Representation Assessment Exposure Captured Company websiteObserved Dr. Elena Varga, Dr. Samir Haddad Current High 1 Sept 2026 Business pressEvidenced Elena Varga and Samir Haddad Aligned Medium 28 Aug 2026 CrunchbaseEvidenced Elena Varga, Samir Haddad Aligned Medium 30 Aug 2026 AI answer · assistant BPerceived Elena Varga Partial High 26 Aug 2026 Decision: Aligned · P(stated value is true) 95% · representations accurate 83% · 2 independent supporting origins
-
Chief executive
Dr. Elena Varga
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → ceo → Dr. Elena VargaNot yet confirmed by the companyChief executive · Quillon Therapeutics states: “Dr. Elena Varga” Source Representation Assessment Exposure Captured Company websiteObserved Dr. Elena Varga Current High 29 Aug 2026 LinkedIn company pageObserved Elena Varga Current Medium 27 Aug 2026 CrunchbaseEvidenced Elena Varga Aligned Medium 25 Aug 2026 AI answer · assistant APerceived Elena Varga Aligned High 23 Aug 2026 Decision: Aligned · P(stated value is true) 84% · representations accurate 84% · 1 independent supporting origin
-
Headquarters
Leiden, Netherlands
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → headquarters → Leiden, NetherlandsNot yet confirmed by the companyHeadquarters · Quillon Therapeutics states: “Leiden, Netherlands” Source Representation Assessment Exposure Captured Company websiteObserved Leiden, Netherlands Current High 20 Aug 2026 Companies registerEvidenced Leiden, Netherlands Aligned Low 6 Sept 2026 CrunchbaseEvidenced Leiden, Netherlands Aligned Medium 4 Sept 2026 Decision: Aligned · P(stated value is true) 97% · representations accurate 97% · 2 independent supporting origins
-
Legal name
Quillon Therapeutics B.V.
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → legal_name → Quillon Therapeutics B.V.Not yet confirmed by the companyLegal name · Quillon Therapeutics states: “Quillon Therapeutics B.V.” Source Representation Assessment Exposure Captured Companies registerEvidenced Quillon Therapeutics B.V. Aligned Low 30 Aug 2026 Decision: Aligned · P(stated value is true) 89% · representations accurate 89% · 1 independent supporting origin
-
Year founded
2021
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → founded_year → 2021Not yet confirmed by the companyYear founded · Quillon Therapeutics states: “2021” Source Representation Assessment Exposure Captured Companies registerEvidenced 2021 Aligned Low 27 Aug 2026 CrunchbaseEvidenced 2021 Aligned Medium 25 Aug 2026 Decision: Aligned · P(stated value is true) 96% · representations accurate 96% · 2 independent supporting origins